Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl-sedation for Flexible Bronchoscopy: A Randomized, Single Blind, Controlled Study of Satisfaction and Safety.

NCT ID: NCT02226328

Last Updated: 2015-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Flexible bronchoscopy almost always requires sedation to be successful. In order to increase the availability of propofol for sedation, non-anaesthesiologist administered propofol sedation has been suggested as an alternative to traditional midazolam/opioid sedation or the general anaesthesia provided by anaesthesiologists.

Hypothesis: Patients undergoing flexible bronchoscopy prefers non-anaesthesiologist administered sedation with propofol as opposed to non-anaesthesiologist administered sedation with midazolam and fentanyl.

Propofol sedation is as safe as midazolam and fentanyl sedation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Flexible Bronchoscopy Sedation Satisfaction Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Propofol sedation

Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.

Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.

Maintenance with 10-20 mg of propofol in case of discomfort.

Group Type EXPERIMENTAL

Propofol sedation

Intervention Type DRUG

Midazolam and Fentanyl sedation

1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.

Maintenance with 1 mg Midazolam in case of discomfort.

Group Type ACTIVE_COMPARATOR

Midazolam and Fentanyl sedation

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol sedation

Intervention Type DRUG

Midazolam and Fentanyl sedation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ATC code: N01AX10 CAS no: 2078-54-8 Midazolam: ATC code: N05CD08 CAS no: 59467-70-8 Fentanyl: ATC code: N01AH01 CAS no: 437-38-7

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Elective flexible bronchoscopy.
2. Willing to be randomised
3. Provide written informed consent

Exclusion Criteria

1. Allergy to contents administered
2. pregnant or nursing
3. \<18 years of age
4. Not able to complete questionnaire
5. Acute condition
6. severe COPD
7. \> ASA II
8. Sleep apnea
9. Risk of aspiration
10. Previously difficulty with anesthesia
11. Difficult airway
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Copenhagen University Hospital at Herlev

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul F Clementsen, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Copenhagen at Gentofte Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gentofte Hospital

Hellerup, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jeppe Thue Jensen, MD

Role: CONTACT

Phone: 004526136032

Email: [email protected]

Paul F Clementsen, Professor

Role: CONTACT

Phone: 0045 39 77 39 77

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul F Clementsen, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-004358-12

Identifier Type: -

Identifier Source: org_study_id